Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly
intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment
due to macular edema secondary to retinal vein occlusion (BRVO or CRVO) to support the
applicability of the phase III study results of BRAVO and CRUISE in this indication, in the
Japanese ethnic patients.